Making cell-free DNA testing accessible to all healthcare providers
Categories: News
Published: 01 August 2025

Advancing Non-Invasive Prenatal Testing at the 32nd International Congress of the Obstetrical and Gynaecological Society of Malaysia (OGSM) 2025

Advancing Non-Invasive Prenatal Testing at the 32nd International Congress of the Obstetrical and Gynaecological Society of Malaysia (OGSM) 2025.  

Gene Solutions Malaysia was pleased to participate in the 32nd International Congress of OGSM, held from 11–13 July 2025 in Penang, Malaysia. 

Established in 1963, OGSM now has over 1,600 active members. At this 32nd International Congress, the event welcomed approximately 1,000 delegates from across the region, bringing together leading O&G professionals to discuss key advancements in women’s health. 

Advancing Non-Invasive Prenatal Testing at the 32nd International Congress of the Obstetrical and Gynaecological Society of Malaysia (OGSM) 2025. Gene Solutions Malaysia was pleased to participate in the 32nd International Congress of OGSM, held from 11–13 July 2025 in Penang, Malaysia. Established in 1963, OGSM now has over 1,600 active members. At this 32nd International Congress, the event welcomed approximately 1,000 delegates from across the region, bringing together leading O&G professionals to discuss key advancements in women’s health. Featured speaker Dr. Tang Hung Sang, Medical Director at Gene Solutions, led a symposium on a promising topic “Re-defining Meaningful NIPT: Smarter Screening, Sharper Focus” which attracted over 100 healthcare professionals. Non-Invasive Prenatal Testing (NIPT), first introduced in 2011 as a safe and reliable screening method, uses cell-free DNA to detect common fetal aneuploidies in pregnant women. This approach reduces the need for invasive diagnostic tests and lowers the risk of miscarriage. Traditionally, NIPT has focused on screening for common chromosomal abnormalities such as Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), Patau syndrome (Trisomy 13) as well as microdeletion syndromes. Dr. Sang emphasized the need to move beyond trisomy-only screening toward a more comprehensive and clinically impactful approach, including carrier screening for mothers during pregancy and testing for single-gene disorders. Bringing up-to-date knowledge of NIPT technology to the congress, key highlights from Dr. Sang’s presentation included: The importance of screening for highly prevalent carrier diseases integrated into NIPT tests. The growing relevance of dominant single-gene disorders, which collectively affect approximately 1 in 600 pregnancies; Clinical scenarios demonstrating how expanded screening can improve pregnancy management, counseling, and outcomes. “Every woman has the right to access prenatal screening to ensure the best care and preparation for her pregnancy. Comprehensive NIPT empowers women to make informed decisions and take proactive steps in their prenatal care,” — said Dr. Tang Hung Sang.   

Featured speaker Dr. Tang Hung Sang, Medical Director at Gene Solutions, led a symposium on a promising topic “Re-defining Meaningful NIPT: Smarter Screening, Sharper Focus” which attracted over 100 healthcare professionals. 

Non-Invasive Prenatal Testing (NIPT), first introduced in 2011 as a safe and reliable screening method, uses cell-free DNA to detect common fetal aneuploidies in pregnant women. This approach reduces the need for invasive diagnostic tests and lowers the risk of miscarriage. 

Traditionally, NIPT has focused on screening for common chromosomal abnormalities such as Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), Patau syndrome (Trisomy 13) as well as microdeletion syndromes. 

Dr. Sang emphasized the need to move beyond trisomy-only screening toward a more comprehensive and clinically impactful approach, including carrier screening for mothers during pregancy and testing for single-gene disorders. 

Bringing up-to-date knowledge of NIPT technology to the congress, key highlights from Dr. Sang’s presentation included: 

  • The importance of screening for highly prevalent carrier diseases integrated into NIPT tests. 
  • The growing relevance of dominant single-gene disorders, which collectively affect approximately 1 in 600 pregnancies; 
  • Clinical scenarios demonstrating how expanded screening can improve pregnancy management, counseling, and outcomes.  

“Every woman has the right to access prenatal screening to ensure the best care and preparation for her pregnancy. Comprehensive NIPT empowers women to make informed decisions and take proactive steps in their prenatal care.” — said Dr. Tang Hung Sang. 

 

 🧬 Introducing triSure: The World’s Most Integrated NIPT 

Introducing triSure: The World’s Most Integrated NIPT At our booth, Gene Solutions introduced triSure, a next-generation NIPT that offers a holistic approach to prenatal screening by combining three dimensions of care: Standard NIPT for aneuploidies and microdeletions. Carrier screening, analyzing 7,535 mutations related to 18 common carrier diseases, such as Thalassemia, Citrin deficiency, and G6PD Deficiency. Dominant single-gene disorder screening, analyzing 7,018 mutations linked to 25 clinically significant conditions, including Achondroplasia, Noonan syndrome, and Osteogenesis imperfecta. With just one blood draw, the test uses advanced technology powered by AI algorithms to offer a comprehensive overview of the baby’s genetic health. triSure has become a leading NIPT solution in Asia, with nearly 1.4 million tests performed to date - solidifying its position as the champion of NIPT in the region.

At our booth, Gene Solutions introduced triSure, a next-generation NIPT that offers a holistic approach to prenatal screening by combining three dimensions of care: 

  • Standard NIPT for aneuploidies and microdeletions. 
  • Carrier screening, analyzing 7,535 mutations related to 18 common carrier diseases, such as Thalassemia, Citrin deficiency, and G6PD Deficiency. 
  • Dominant single-gene disorder screening, analyzing 7,018 mutations linked to 25 clinically significant conditions, including Achondroplasia, Noonan syndrome, and Osteogenesis imperfecta. 

With just one blood draw, the test uses advanced technology powered by AI algorithms to offer a comprehensive overview of the baby’s genetic health.  

triSure has become a leading NIPT solution in Asia, with nearly 1.4 million tests performed to date – solidifying its position as the champion of NIPT in the region.  

Introducing triSure: The World’s Most Integrated NIPT At our booth, Gene Solutions introduced triSure, a next-generation NIPT that offers a holistic approach to prenatal screening by combining three dimensions of care: Standard NIPT for aneuploidies and microdeletions. Carrier screening, analyzing 7,535 mutations related to 18 common carrier diseases, such as Thalassemia, Citrin deficiency, and G6PD Deficiency. Dominant single-gene disorder screening, analyzing 7,018 mutations linked to 25 clinically significant conditions, including Achondroplasia, Noonan syndrome, and Osteogenesis imperfecta. With just one blood draw, the test uses advanced technology powered by AI algorithms to offer a comprehensive overview of the baby’s genetic health. triSure has become a leading NIPT solution in Asia, with nearly 1.4 million tests performed to date - solidifying its position as the champion of NIPT in the region.

We extend our sincere thanks to OGSM for the opportunity to share our insights and contribute to the advancement of prenatal care in the region. 

Learn more about triSure at: https://genesolutions.com/our-test/trisure-procare